Targeting p53 in chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Targeting p53 in chronic lymphocytic leukemia

Published:2020-10-19 Issue:12 Volume:24 Page:1239-1250
ISSN:1472-8222
Container-title:Expert Opinion on Therapeutic Targets
language:en
Short-container-title:Expert Opinion on Therapeutic Targets

Author:

Moia Riccardo¹^ORCID,Boggione Paola¹,Mahmoud Abdurraouf Mokhtar¹,Kodipad Ahad Ahmed¹,Adhinaveni Ramesh¹,Sagiraju Sruthi¹,Patriarca Andrea¹^ORCID,Gaidano Gianluca¹^ORCID

Affiliation:

1. Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy

Funder

Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728222.2020.1832465

Reference102 articles.

1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes

2. Chronic lymphocytic leukaemia

3. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment

4. Duffy MJ, Crown J. Drugging “Undruggable” genes for cancer treatment: are we making progress?Int J Cancer. 2020 Online ahead of print.].

5. Unravelling mechanisms of p53-mediated tumour suppression

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined Delivery of miR-15/16 through Humanized Ferritin Nanocages for the Treatment of Chronic Lymphocytic Leukemia;Pharmaceutics;2024-03-14

2. Bayesian inference for identifying tumour-specific cancer dependencies through integration of ex-vivo drug response assays and drug-protein profiling;BMC Bioinformatics;2024-03-08

3. Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions;Hematological Oncology;2023-11-08

4. TP53 Gene 72 Arg/Pro (rs1042522) single nucleotide polymorphism increases the risk and the severity of chronic lymphocytic leukemia;Frontiers in Oncology;2023-10-16

5. Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia;Applied Health Economics and Health Policy;2023-08-22